Global Partners L.P. (GLP)
NYSE NYSE Primary 
3 Reasons Why Growth Investors Shouldn't Overlook Global Partners (GLP)
Global Partners (GLP) possesses solid growth attributes, which could help it handily outperform the market.
Jefferies trims Novo Nordisk target as GLP-1 pricing erosion and oral Wegovy launch uncertainty cloud first quarter
The broker retains its hold rating, warning that overall portfolio growth may stall even as the oral weight-loss pill gains traction Jefferies has trimmed its price target on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant, to DKK270 from DKK275, maintaining a 'hold' rating ahead of first-quarter results. The change came as the broker flagged mounting uncertainty around GLP-1 pricing, oral Wegovy's launch trajectory and the risk that the new pill cannibalises rather than grows the overall franchise.
GLP-1 And Private Labels Are A Genuine Threat To General Mills But I May Buy This Dip
General Mills (GIS) is rated a soft buy as its valuation appears attractive after a prolonged decline, despite recent underperformance. GLP-1 appetite-suppressing drugs and rising private label popularity pose headwinds to GIS's revenue and brand strength. GIS's fundamentals show a low TTM GAAP PE of 9.21, strong ~12% net income margins, but concerning 6.5% YOY revenue decline and shrinking EPS.
Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock?
CAH sees GLP-1 drugs boost revenue growth, but margins lag as strong demand lifts volumes without significantly improving profitability.
Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern
New trial data complicates the competitive picture in the fast-growing obesity drug market Eli Lilly and Co's (NYSE:LLY) experimental weight-loss and diabetes drug retatrutide has shown a side-effect profile broadly comparable to leading treatments, but new data flagging an unusual skin reaction could give prescribers pause as the race to challenge Novo Nordisk's dominance intensifies. Lilly reported headline results from the first phase three trial of retatrutide in type 2 diabetes, showing patients achieved 16.8% weight loss and a 1.1 percentage point reduction in HbA1c, a standard measure of long-term blood sugar control, after 40 weeks at the 12mg dose.
Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.
Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum?
LLY stock falls 6% after an HSBC downgrade flagged persisting U.S. pricing pressure, rising market competition and compounded tirzepatide risks, despite strong GLP-1 demand.
Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target
Structure Therapeutics (GPCR) reported highly positive Phase 2 ACCESS II data for aleniglipron, achieving ~16% placebo-adjusted weight loss with strong statistical significance and no plateau. Aleniglipron's oral, non-peptide, once-daily profile with injectable-level efficacy and improved tolerability positions GPCR as a potential best-in-class oral GLP-1 therapy. GPCR's $1.4B cash position funds operations into 2028, supporting Phase 3 development and pipeline expansion without immediate dilution risk.
3 Companies at the Forefront of the GLP-1 Pill Wars
Though the first GLP-1 agonists date back more than 20 years, it's only in the last couple of years that they began to dominate the pharmaceutical space for their massive potential as weight loss drugs. With some estimates placing the market at nearly $63 billion in early 2026, forecasts call for the GLP-1 industry to roughly triple over the coming decade.
Eli Lilly's Employer Push Could Unlock New GLP-1 Demand
The world's most valuable pharmaceutical stock, Eli Lilly and Company NYSE: LLY, has continued to assert its dominance in the weight-loss and diabetes drug market in 2026.
Will Policy Shifts Accelerate Demand for Eli Lilly's GLP-1 Drugs?
LLY is likely to see stronger demand for its GLP-1 drugs as Medicare expands coverage and the company prepares to launch an oral obesity treatment.
Can Novo Nordisk's Hims & Hers Deal Revive Its GLP-1 Momentum?
NVO partners with HIMS to expand access to Ozempic and Wegovy via telehealth, aiming to shift patients from compounded GLP-1s to FDA-approved drugs.
